These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 23092556)
21. Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Redondo-Müller MA; Stevanovic-Walker M; Barker S; Puddefoot JR; Vinson GP Endocr Relat Cancer; 2008 Mar; 15(1):277-88. PubMed ID: 18310294 [TBL] [Abstract][Full Text] [Related]
22. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Bae DG; Kim TD; Li G; Yoon WH; Chae CB Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646 [TBL] [Abstract][Full Text] [Related]
23. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. Anandanadesan R; Gong Q; Chipitsyna G; Witkiewicz A; Yeo CJ; Arafat HA J Gastrointest Surg; 2008 Jan; 12(1):57-66. PubMed ID: 18026817 [TBL] [Abstract][Full Text] [Related]
24. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Ohnuma Y; Toda M; Fujita M; Hosono K; Suzuki T; Ogawa Y; Amano H; Kitasato H; Hayakawa K; Majima M Biomed Pharmacother; 2009 Feb; 63(2):136-45. PubMed ID: 18691848 [TBL] [Abstract][Full Text] [Related]
25. Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice. Gu JW; Young E; Busby B; Covington J; Johnson JW Cancer Biol Ther; 2009 Mar; 8(6):514-21. PubMed ID: 19242105 [TBL] [Abstract][Full Text] [Related]
26. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8. Harada K; Supriatno ; Yoshida H; Sato M Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203 [TBL] [Abstract][Full Text] [Related]
27. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor. Wang D; Tang F; Wang S; Jiang Z; Zhang L Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122 [TBL] [Abstract][Full Text] [Related]
28. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M Hum Cell; 2007 Feb; 20(1):1-9. PubMed ID: 17506771 [TBL] [Abstract][Full Text] [Related]
29. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Du N; Feng J; Hu LJ; Sun X; Sun HB; Zhao Y; Yang YP; Ren H Oncol Rep; 2012 Jun; 27(6):1893-903. PubMed ID: 22426690 [TBL] [Abstract][Full Text] [Related]
30. OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis. Rebbaa A; Patil G; Yalcin M; Sudha T; Mousa SA Cancer Lett; 2013 May; 332(1):55-62. PubMed ID: 23348692 [TBL] [Abstract][Full Text] [Related]
31. A precision-guided MWNT mediated reawakening the sunk synergy in RAS for anti-angiogenesis lung cancer therapy. Su Y; Hu Y; Wang Y; Xu X; Yuan Y; Li Y; Wang Z; Chen K; Zhang F; Ding X; Li M; Zhou J; Liu Y; Wang W Biomaterials; 2017 Sep; 139():75-90. PubMed ID: 28595131 [TBL] [Abstract][Full Text] [Related]
32. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Hasegawa M; Mikami S; Oya M Prostate; 2010 Feb; 70(2):162-9. PubMed ID: 19760626 [TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Otake AH; Mattar AL; Freitas HC; Machado CM; Nonogaki S; Fujihara CK; Zatz R; Chammas R Cancer Chemother Pharmacol; 2010 May; 66(1):79-87. PubMed ID: 19771429 [TBL] [Abstract][Full Text] [Related]
35. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Bergman Jungeström M; Thompson LU; Dabrosin C Clin Cancer Res; 2007 Feb; 13(3):1061-7. PubMed ID: 17289903 [TBL] [Abstract][Full Text] [Related]
36. Angiotensin II promotes the progression of human gastric cancer. Huang MM; Guo AB; Sun JF; Chen XL; Yin ZY Mol Med Rep; 2014 Mar; 9(3):1056-60. PubMed ID: 24424956 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the therapeutic efficacy of a VEGFR2-blocking antibody using sodium-iodide symporter molecular imaging in a tumor xenograft model. Cheong SJ; Lee CM; Kim EM; Uhm TB; Jeong HJ; Kim DW; Lim ST; Sohn MH Nucl Med Biol; 2011 Jan; 38(1):93-101. PubMed ID: 21220132 [TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate. Chintalapati M; Truax R; Stout R; Portier R; Losso JN J Agric Food Chem; 2009 Jun; 57(12):5201-10. PubMed ID: 19476359 [TBL] [Abstract][Full Text] [Related]
39. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. Okazaki M; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Tajima H; Ninomiya I; Fujimura T; Ohta T Cancer Lett; 2014 Dec; 355(1):46-53. PubMed ID: 25224569 [TBL] [Abstract][Full Text] [Related]
40. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]